Cloud Pharmaceuticals, a therapeutics company focused on cloud-based drug design and development, has ratified its board of directors. Members of the board include Cloud Pharmaceuticals chairman and CEO Ed Addison, chief scientific officer Shahar Keinan, Ph.D., and chief information officer Lawrence Husick. Other members of the board include:
Rob Armstrong, Ph.D. Armstrong is an independent consultant in the pharmaceutical industry. His extensive discovery and preclinical development experience is of particular value to Cloud Pharmaceuticals as it works to develop partnering relationships in the drug design and development market. Previously, he acted as vice president, discovery chemistry and research technologies for Eli Lilly. Prior, he was director of small molecule discovery at Amgen and was associate professor of biochemistry at UCLA.